liraglutide · GLP-1 receptor agonist

Saxenda

Official-label efficacy with list-price reference and generic-market context; patient quoting remains manual-review.

Partial

Efficacy anchors

1 anchors

  • Primary label anchor

    LabelWeek 56

    Trial: Study 1

    Adults with obesity or overweight with at least one weight-related comorbidity

    Type 2 diabetes population: 5.4% at Week 56.

    Post-diet maintenance population: 4.9% at Week 56.

    7.4%

    Saxenda Prescribing Information

    Feb 1, 2026

    Why this number?

    Primary Saxenda label anchor from Study 1 at Week 56. Other labeled populations were 5.4% and 4.9%.

    Dose context: 3 mg

Price anchors

1 anchors

  • Official list price

    List

    Dose context: All doses

    Program: Official list price

    Generic liraglutide launch context: 2025-08-28.

    $1,349.02 list

    Saxenda list price page

    Apr 19, 2026 3:19 AM

    Why this number?

    Official list price page still contains legacy savings language, so this row should remain manual-review for quoting.

    Official list-price reference only; actual patient cost depends on coverage or generic access.

    Patient segment: reference_only

    Official list price is stable, but live patient quoting is messy because the legacy savings program was discontinued for new enrollees and generic liraglutide is now on the market. The Saxenda Savings Offer was discontinued for new enrollees on June 30, 2023; previously activated offers could be used through December 31, 2023. Teva announced FDA approval and launch of generic Saxenda (liraglutide injection) as the first generic GLP-1 indicated for weight loss.

Source ledger

4 linked

Timeline

Change history

View all changes →
medium severity

Observed Saxenda price anchor official_list_price

Observed Saxenda official_list_price at $1349.02/month from Saxenda list price page.

View source
low severity

Observed Saxenda efficacy anchor label_post_diet_maintenance

Observed Saxenda label_post_diet_maintenance efficacy anchor at 4.9% from Saxenda Prescribing Information.

View source
low severity

Observed Saxenda efficacy anchor label_type2_diabetes

Observed Saxenda label_type2_diabetes efficacy anchor at 5.4% from Saxenda Prescribing Information.

View source
low severity

Observed Saxenda efficacy anchor label_primary_obesity

Observed Saxenda label_primary_obesity efficacy anchor at 7.4% from Saxenda Prescribing Information.

View source